[ Price : $8.95]
FDA approves expanded indications for Celltrions Yuflyma (adalimumab-aaty) to include treating hidradenitis suppurativa in adolesc...[ Price : $8.95]
FDA names the first nine voucher recipients under the recently launched Commissioners National Priority Voucher pilot review progr...[ Price : $8.95]
FDA approves Azurity Pharmaceuticals Ferabright (ferumoxytol injection), an iron-based contrast agent for magnetic resonance imagi...[ Price : $8.95]
Sen. Jim Banks (R-IN) urges FDA to step up inspections of pharmaceutical manufacturing facilities abroad, citing persistent qualit...[ Price : $8.95]
Attorneys from Mintz warn that FDAs recent safety communication on acetaminophen and autism may signal a departure from long-stand...[ Price : $8.95]
FDA accepts for priority review a Johnson & Johnson supplemental NDA for Akeega (niraparib and abiraterone acetate dual-action tab...[ Price : $8.95]
Novartis reports that a Phase 3 trial of its oral complement inhibitor Fabhalta (iptacopan) showed the therapy slowed kidney funct...[ Price : $8.95]
Two academic researchers urge FDA to require a Drug Facts box in direct-to-consumer ads so consumers can understand a drugs benefi...